PRESS CENTER
新聞中心
News
-
2024/01/24Merck Signs MoU with Mycenax Biotech to Drive Innovation in Bioprocessing Technology
-
2023/06/15Mycenax Biotech has signed an MOU with StemCyte to strengthen its one-stop service chain for allogeneic cell therapy
-
2023/06/01Construction Commencement of Mycenax Biotech's Cell Therapy Pilot Plant
-
2022/09/21Mycenax signs MoU with KriSan Biotech: Building ADC Industry Value Chain
-
2022/07/28JCR Pharmaceuticals invests in Mycenax Biotech, becomes largest shareholder
-
2022/05/30Mycenax re-elected Dr. Allen Y. Chao as independent director
-
2022/01/18Grand Opening Ceremony of Mycenax’s New GMP Manufacturing Plant, Zhunan Science Park
-
2021/08/26Mycenax Reports 2022 H1 EPS of NT$0.32 with business expansion from traditional biologics to allogeneic cell therapy and emerging biologics.
-
2021/08/26Mycenax and Cytiva Enable First Continuous Manufacturing Process Development Satellite Laboratory in Taiwan
-
2021/06/08Mycenax signs an MOU with CHO PHARMA, cooperating to expand the production and application of next-generation antibodies
- 1
- 2